PanGen Biotech, Inc. engages in the production and sales of biopharmaceuticals. Its products include biosimilar erythropoietin (EPO), recombinant Factor VIII, biosimilar Aflibercept, recombinant anti-SFTSV Ab, and biosimilar G-CSF. The company was founded on January 29, 2010 and is headquartered in Suwon-si, South Korea.